[ad_1]
BOSTON, March 7, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapies to treat difficult-to-treat cancers, today announced Lara S. Sullivan, President and Executive Managing Director, will participate in a fireside chat at the Leerink Partners Global Biopharmaceutical Conference, Management, on Wednesday, March 13, 2024, at 8:40 a.m. ET in Miami Beach, Florida Members will also host one-on-one meetings with investors.
A live webcast and presentation replay will be available on the Events and Presentations page of the Investor Relations section of Pyxis Oncology’s website at ir.pyxisoncology.com.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on overcoming difficult-to-treat cancers. The company is efficiently building next-generation therapies with single and combination therapy potential. PYX-201 is an antibody drug conjugate (ADC) uniquely targeting EDB+FN within the tumor stroma, while PYX-106 is a fully human Siglec-15 targeting antibody designed to block T cells Inhibition of proliferation and function. It is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and address the underlying pathology caused by cancer that leads to its uncontrolled proliferation and immune escape. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors that are resistant to current standards of care. To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.
forward-looking statements
This press release contains forward-looking statements made within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “could,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “could” and other . , “possible”, “goal”, “ongoing”, “plan”, “potential”, “forecast”, “project”, “should”, “be”, “will”, “would” or negate the words or plural forms of the word, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be realized or occur, and actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the factors identified herein and those discussed in the section titled “Risk Factors” in Pyxis Oncology’s Annual Report on Form 10-K for the year ended December 31, 2022. Pyxis Oncology’s Quarterly Report on Form 10-Q for the Quarter ended March 31, 2023, Pyxis Oncology’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2023, Pyxis Oncology’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2023 reports for the quarter ended September 30, 2023 and our other filings, each of which is filed with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is impossible for our management to predict all risk factors or to assess the impact of all factors on our business or the extent to which any factor or combination of factors may cause such risks. Actual results may differ materially from those contained in any forward-looking statements. In addition, “we believe” statements and similar statements reflect our beliefs and opinions regarding the subject matter involved. These statements are based on information available to us as of the date hereof, and while we believe that such information forms a reasonable basis for such statements, such information may be limited or incomplete and our statements should not be construed as indicating We have conducted an exhaustive investigation or review of all relevant information that may be available. These statements are inherently uncertain and investors are cautioned not to place undue reliance on these statements. Except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of such statement.
Pyxis Oncology Contact
Pamela Connelly
Chief Financial Officer and Chief Operating Officer
ir@pyxisoncology.com
[ad_2]
Source link